The added value of hybrid ventilation/perfusion SPECT/CT in patients with stable COPD or apparently healthy smokers. Cancer-suspected CT findings in the lungs are common when hybrid imaging is used

Abstract: Ventilation/perfusion (V/P) single-photon emission computed tomography (SPECT) is recognized as a diagnostic method with potential beyond the diagnosis of pulmonary embolism. V/P SPECT identifies functional impairment in diseases such as heart failure (HF), pneumonia, and chronic obstructive pulmonary disease (COPD). The development of hybrid SPECT/computed tomography (CT) systems, combining functional with morphological imaging through the addition of low-dose CT (LDCT), may be useful in COPD, as these patients are prone to lung cancer and other comorbidities. The aim of this study was to investigate the added value of LDCT among healthy smokers and patients with stable COPD, when examined with V/P SPECT/CT hybrid imaging. Sixty-nine subjects, 55 with COPD (GOLD I–IV) and 14 apparently healthy smokers, were examined with V/P SPECT and LDCT hybrid imaging. Spirometry was used to verify COPD grade. Only one apparently healthy smoker and three COPD patients had a normal or nearly normal V/P SPECT. All other patients showed various degrees of airway obstruction, even when spirometry was normal. The same interpretation was reached on both modalities in 39% of the patients. LDCT made V/P SPECT interpretation more certain in 9% of the patients and, in 52%, LDCT provided additional diagnoses. LDCT better characterized the type of emphysema in 12 patients. In 19 cases, tumor-suspected changes were reported. Three of these 19 patients (ie, 4.3% of all subjects) were in the end confirmed to have lung cancer. The majority of LDCT findings were not regarded as clinically significant. V/P SPECT identified perfusion patterns consistent with decompensated left ventricular HF in 14 COPD patients. In 16 patients (23%), perfusion defects were observed. HF and perfusion defects were not recognized with LDCT. In COPD patients and long-time smokers, hybrid imaging had added value compared to V/P SPECT alone, by identifying patients with lung malignancy and more clearly identifying emphysema. V/P SPECT visualizes comorbidities to COPD not seen with LDCT, such as pulmonary embolism and left ventricular HF.

Background
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and patients with COPD are prone to comorbid diseases such as heart failure, ischemic heart disease, and lung malignancy. Ventilation/perfusion (V/P) single-photon emission computed
tomography (SPECT) is a nuclear medicine method that is used primarily for pulmonary embolism (PE) diagnosis, but which has also been shown to be a sensitive method by which to detect and stage the degree of airway obstruction and other parenchymal changes. Moreover, SPECT/computed tomography (CT) hybrid systems are becoming commonly used. The hybrid SPECT/CT system is a dual-imaging modality technique whose clinical application has, so far, had the most impact in oncological diseases as a result of improved sensitivity and specificity, and because it combines co-registration of anatomical and functional data. This system can improve the staging and monitoring of treatment. As nuclear medicine procedures have the ability to visualize functional changes before structural changes occur, the addition of a CT procedure can allow morphological correlation of regions with physiological variants. It can also be used for correction for photon attenuation. Regarding the lungs, low-dose CT (LDCT) has been discussed as a screening method for lung cancer among elderly persons with an elevated risk, eg, smokers, but guidelines for if and whom to screen have not yet been established. In V/P SPECT, co-registered CT has been used by some authors to improve the specificity in PE diagnosis, but the value of adding LDCT has otherwise been insufficiently studied. The objective of this study was therefore to investigate what the added value of LDCT was among healthy smokers and patients with stable COPD when examined with V/P SPECT/CT hybrid imaging.

Subjects and methods

This prospective study was performed with approval from the Regional Ethical Committee in Lund, Sweden. All 69 subjects gave their informed consent of participation. Patients who were either apparently healthy current or former long-time smokers (n=14; mean age ± standard deviation = 69±3 years; seven women, smoking 24–40 pack-years) or patients with stable COPD (n=55; mean age ± standard deviation = 68±5 years; 25 women; Global initiative for chronic Obstructive Lung Disease [GOLD] stage I–IV, smoking 15–159 pack-years), were examined with V/P SPECT and LDCT in a hybrid system. To be included in the study subjects had to be over the age of 40 years and clinically stable and, in the case of COPD patients, had been without any exacerbations during the 4 weeks prior to inclusion. Patients that did not fulfill the inclusion criteria were excluded from the study. Spirometry was performed in accordance with the guidelines of the American Thoracic Society to measure the ventilatory impairment and validate the GOLD stage. The V/P SPECT images were first interpreted independently of the CT examination by an experienced nuclear physician. The assessment was done in accordance with the guidelines of the European Association of Nuclear Medicine (EANM). Then, the V/P SPECT images were interpreted in combination with the CT images. This was done together with an experienced chest radiologist. V/P SPECT/CT fusion images were also available at this time. It was noted whether the interpretation of the examination was the same as the one made without use of LDCT, if LDCT helped to make the interpretation more definite, or if LDCT added new diagnoses not observed with V/P SPECT. The physicians who reviewed the V/P SPECT and LDCT images were blinded to all other information. Suspected tumor changes in LDCT were reported and follow-up was performed by referring physicians in accordance with local guidelines of Skåne University Hospital, Lund, Sweden.

V/P SPECT/CT protocol

All examinations were performed with a Precedence SPECT/CT system (Philips Healthcare, Best, the Netherlands), which combines a dual-head gamma camera with a Brilliance 16-slice CT scanner. The procedure was begun with a CT overview image and continued with diagnostic LDCT (120 kV, 20 mAs/slice, 16×1.5 collimator, 0.5 second rotation time, and pitch of 0.813). The CT examination was not used for attenuation correction, but to colocalize the morphological and functional changes visualized in either of the two modalities. The CT examination was performed during tidal breathing. The CT acquisition was followed by the protocol for V/P SPECT, which has been described earlier and which is in accordance with the guidelines of EANM.

For the V/P SPECT, administration of ventilation and perfusion agents was performed in the supine position so as to minimize gravitational gradients. The V/P SPECT procedure starts with ventilation scintigraphy upon inhalation of very fine 99mTc-labeled solid graphite particles (Technegas; Cyclomedica, Lucas Heights, NSW, Australia), which are mainly deposited in the alveoli by diffusion. Doses of 25–30 MBq in the lungs are needed for ventilation studies. Perfusion tomography follows immediately after ventilation, without changing the position of the patient. For perfusion scintigraphy, 120 MBq of technetium-labeled particles of macroaggregates of human albumin (99mTc-MAA) are injected intravenously. A general purpose collimator, 64×64 matrix, is used. The total number of projections is 128 (64 stops for each of the two gamma camera heads). Each stop is 10 seconds for the ventilation study, and, for the perfusion...
study, 5 seconds. This allows a total acquisition time of 20 minutes. For V/P SPECT reconstruction, ordered-subset expectation maximization iterative reconstruction with eight subsets and two iterations is used.

**Results**

**V/P SPECT in apparently healthy smokers**

Thirteen of the 14 apparently healthy smokers demonstrated various degrees of airway obstruction on V/P SPECT, although spirometry did not detect decreased ventilation capacity or airflow limitation. Only one smoker had a completely normal V/P distribution.

Five subjects showed perfusion defects in ventilated regions (mismatch). Six apparently healthy smokers showed matched V/P defects typical for emphysema, with extension of 5%–25%. One subject showed V/P impairment that is typical for pneumonia.

**V/P SPECT in COPD patients**

Three COPD patients had nearly normal ventilation according to V/P SPECT; one patient in GOLD stage I and two patients in GOLD stage II. All of the others showed different degrees of airway obstruction. Emphysema was identified in 48 patients, with extension of 5%–80%. In ten of the 55 patients, vascular defects (mismatch) were observed. Moreover, V/P SPECT identified 14 patients with a perfusion pattern consistent with pulmonary congestion typical for decompensated left ventricular HF (Figure 1).

**Figure 1** Patient with COPD, LHF, and a small tumor.

**Notes:** (A) Frontal slice of ventilation SPECT (a) showing uneven distribution of ventilation with deposition of Technegas in central airways, which is a typical sign of airway obstruction. Corresponding perfusion SPECT (b) and CT image (c) are shown. The blue arrow in (c) shows thickening of the airway wall that is typical of COPD. (B) Transverse slices of ventilation SPECT (a), with corresponding perfusion SPECT (b). In the CT image (c), a small tumor (1 cm; red arrow) is visualized. In the corresponding V/P SPECT image (b) a small perfusion defect is observed (red arrow). (C) Sagittal slice showing fusion ventilation SPECT/CT (a), with corresponding perfusion SPECT/CT image (b) that shows antigravitational redistribution of perfusion, typical for LHF (yellow arrow), which is not visible on CT (c) or ventilation images (nonsegmental mismatch).

**Abbreviations:** COPD, chronic obstructive pulmonary disease; CT, computed tomography; LHF, left ventricular heart failure; SPECT, single-photon emission computed tomography.
Table 1: Added value of LDCT with V/P SPECT versus V/P SPECT alone

<table>
<thead>
<tr>
<th>Impact of LDCT</th>
<th>n  (69)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Same interpretation, nothing new</td>
<td>27</td>
<td>39</td>
</tr>
<tr>
<td>Interpretation more clear/certain</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Additional diagnosis that did not change treatment</td>
<td>27</td>
<td>39</td>
</tr>
<tr>
<td>Additional diagnosis that led to changed or new treatment</td>
<td>9</td>
<td>13</td>
</tr>
</tbody>
</table>

**Abbreviations:** LDCT, low-dose computed tomography; V/P SPECT, ventilation/perfusion single-photon emission computed tomography.

**Additional value of LDCT**

The same interpretation on both modalities was reached in 27 subjects (39%). Interpretation of V/P SPECT was more definite in six patients (9%). CT provided additional diagnoses in 36 patients (52%) (Table 1). Table 2 shows the type and distribution of the LDCT findings that were found among the 36 patients with additional diagnoses on LDCT in Table 1. Most of the diagnoses were not regarded as clinically significant. LDCT better characterized the type of emphysema in 12 patients. In 19 cases, nodular or tumor-suspected findings in LDCT images were reported (Table 2).

Nine patients (13%) needed further follow-up and, of these, three patients (4.3%) were found to have lung cancer (Figure 2). One of the patients died due to this malignancy during the follow-up period.

LDCT did not recognize the decompensation or the vascular defects seen in V/P SPECT images in any case.

**Discussion**

This study shows that the strength of hybrid imaging in patients with COPD and long-term smokers is primarily in detecting tumor-suspected changes and lung cancer. COPD patients are known to be prone to tumor development, and screening of selected high-risk patients using LDCT has been recommended by some authors and been shown to reduce lung cancer mortality by 20% compared with chest radiography. However, because there are radiation risks in using LDCT lung cancer screening, it should be performed only on current or former tobacco smokers. In this study, nodular changes were observed in as many as 19 cases (five apparently healthy current or former smokers and 14 COPD patients) (Table 2), possibly causing anxiety for patients and problems for the clinicians requested to follow-up. Nine patients (13%) needed further follow-up and, of these, three patients (4.3%) were found to have lung cancer. V/P SPECT might provide a more comprehensive functional assessment that can guide decisions about surgery (Figure 2) in patients finally diagnosed with cancer, as suggested by Yuan et al.

An interesting finding in this study was that 13 out of 14 apparently healthy smokers showed various degrees of obstructive airway changes. V/P SPECT has the possibility to assess how ventilation and perfusion are affected and to detect early functional changes in small airways. These findings are in agreement with those of Rodriguez-Roisin et al, who measured V/P ratios in the lung using the multiple inert gas elimination technique and showed high sensitivity to COPD pathologies.

A recent paper by Jobse et al further confirmed that V/P mismatching progressively increased during cigarette smoke exposure in mice. While spirometry offers a simple test for COPD, it only provides a global measure, is insensitive to early disease, and cannot explore the heterogeneity of COPD. V/P SPECT greatly augments our understanding of the disease and offers the possibility to see how various pathologies affect gas exchange. V/P SPECT has the ability to visualize early functional impairment leading to COPD that may not be obvious, even at a higher resolution, in anatomical imaging systems such as CT.

The primary indication for the use of V/P SPECT is PE. Previous studies have shown that V/P SPECT alone has less than 4% nondiagnostic examinations, as well as high sensitivity and specificity. Because of the high sensitivity and specificity of V/P SPECT alone, it is not generally recommended to use a hybrid system for PE diagnosis, as argued by some authors. As this study shows, some patient groups may, however, benefit from the additional anatomical information that LDCT provides, especially patients with an elevated risk of lung malignancy. Therefore, it might be appropriate to recommend the use of hybrid imaging among patients with COPD but also among apparently healthy long-term smokers. This needs to be studied further in larger studies. In the light of the increasing awareness regarding the overuse of CT, as noted in several publications in recent years, it is, however, not

**Table 2: Distribution of CT findings among patients with additional diagnoses on LDCT**

<table>
<thead>
<tr>
<th>LDCT findings</th>
<th>n° (36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nodular changes</td>
<td>19</td>
</tr>
<tr>
<td>Pleural effusion (minor)</td>
<td>1</td>
</tr>
<tr>
<td>Emphysema (better characterization)</td>
<td>12</td>
</tr>
<tr>
<td>Atelectasis</td>
<td>2</td>
</tr>
<tr>
<td>Bronchiolitis or bronchiectasis</td>
<td>4</td>
</tr>
<tr>
<td>Parenchymal changes</td>
<td>4</td>
</tr>
<tr>
<td>Vascular malformation (minor)</td>
<td>1</td>
</tr>
<tr>
<td>Pulmonary cyst</td>
<td>1</td>
</tr>
</tbody>
</table>

**Note:** The same patient could have more than one additional finding.

**Abbreviations:** CT, computed tomography; LDCT, low-dose computed tomography.
acceptable to advocate the extra radiation delivered from CT for every patient with suspected PE as the prevalence of PE is as low as 10%–30% in most study populations.\textsuperscript{15,25,26}

A better routine for selecting patients who may benefit from hybrid imaging is therefore needed to solve the problem of false positives in tumor diagnosis.

It is known that COPD patients often have clinically significant pulmonary vascular changes.\textsuperscript{27} In this study, as well as in an earlier study by our group,\textsuperscript{1} it was shown that vascular defects exist both in apparently healthy smokers and COPD patients. The effects of the vascular changes can be shown with V/P SPECT. Estépar et al also found distal pruning of the pulmonary blood vessels using CT among smokers.\textsuperscript{28}

We have many diagnostic imaging modalities at our disposal today. The question is how best to use them for the benefit of our patients. To decide on the most appropriate diagnostic modality, it is most important to focus on the clinical question. When hybrid imaging is used for the lungs, this study shows that, at least among smokers and patients with COPD, the LDCT images need to be evaluated with malignancy in mind. It is not adequate to regard the LDCT images only as a way to localize physiological findings. This is a new challenge for nuclear medicine physicians.

**Limitations**

The number of patients in this study is limited, and larger studies will be needed. The finding that LDCT identifies previously undetected lung cancer in this group of patients is in line with previous studies.\textsuperscript{6,11} This is, however, to our knowledge, the first study that shows this in patients examined with a hybrid system. SPECT/CT acquisition of the chest constitutes a challenge due to respiratory movements, which can cause image artifacts and thus decrease diagnostic accuracy. All images were, however, regarded as diagnostic by the interpreters. To reduce the risk of artifacts, the CT was not used for attenuation correction.

**Conclusion**

In patients with COPD and apparently healthy long-time smokers, V/P SPECT/CT hybrid imaging appears to have added value compared to V/P SPECT alone. The additional value of LDCT in this group was primarily the ability to identify patients with suspected lung malignancy and to more clearly identify and categorize emphysema. V/P SPECT can visualize complications of COPD, such as PE and decompensated heart failure, that cannot be seen with LDCT.
Acknowledgments
This study was funded in part by Region of Scania (ALF) and the Swedish Heart-Lung Foundation. We want to thank the staff at the Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden.

Disclosure
The authors report no conflicts of interest in this work.

References